-

Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences.

  • H.C. Wainwright Virtual BioConnect 2022 Conference. On-demand presentation available Monday, January 10, 2022, beginning at 7:00 a.m. EST thru Thursday, January 13, 2022 (access here)
  • J.P Morgan 40th Annual Healthcare Conference. Presentation to be hosted on Thursday, January 13, 2022 at 9:45 am EST (access here)

Interested parties can also register and access these presentations under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com.

ABOUT AURINIA

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

Contacts

Investor and Corporate:
Dana Lynch, Corporate Communications & IR
dlynch@auriniapharma.com

Industry:

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH
Release Versions
English

Contacts

Investor and Corporate:
Dana Lynch, Corporate Communications & IR
dlynch@auriniapharma.com

More News From Aurinia Pharmaceuticals Inc.

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study’s primary endpoint is the proportion of patients achieving complete renal response (CRR)...

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death...

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress...
Back to Newsroom